World Sickle Cell Day

Many Pharmaceuticals companies are working across the globe towards the development of new treatment therapies for Alpha-1 Anti-trypsin Deficiency to fulfil the unmet needs of Anti-trypsin Deficiency Therapeutic market as discussed in the previous article. The Alpha-1 Anti-trypsin Deficiency market is expected to c...

Antitrypsin deficiency, also called AAT deficiency (Alpha-1 Antitrypsin deficiency) is an inherited disease characterized by severe problems that make difficult to breathe. Along with lung disease, it can also cause serious issues in the liver too. Mutations in the SERPINA1 gene, whose primary function is to transc...

AstraZeneca-Daiichi breast cancer treatment scored promising results The breast cancer drug trastuzumab deruxtecan developed by AstraZeneca and Daiichi Sankyo showed positive results in a metastatic breast cancer trial. AstraZeneca remunerated Daiichi Sankyo USD 1.35 billion upfront and guaranteed up to USD 6.9 ...

SMA (Spinal Muscular Atrophy) - a disease that takes away the physical strength of people by affecting the motor nerve cells in the spinal cord, also people have a problem in walking, eating, or breathing. Spinal Muscular Atrophy market size is increasing at a CAGR of 10.42% for the study period (2017-2028). ...

Spinal muscular atrophy (SMA) being a rare genetic neuromuscular disorder results in progressive muscle weakness and atrophy. It affects the part of the nervous system that controls voluntary muscle movement. Spinal Muscular Atrophy Current therapeutic management revolves around supportive and multidisciplinary car...

Spinal Muscular Atrophy (SMA) is a genetic disorder that affects the part of the nervous system which controls the voluntary movement of limbs and muscles. SMA results in the loss of motor neurons in the Spinal Cord. SMA is one of the most common causes of infant mortality and mobility impairment. Spinal Muscular A...